TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...
UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...
GRI Bio, Inc., a biotechnology firm focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases, announced that CEO Marc Hertz took part in a Virtual Investor CEO Connect ...
GRI Bio on track to launch Phase 2a biomarker study for lead program, GRI-0621 a type 1 invariant NKT (iNKT) antagonist for the treatment of IPF before year end LA JOLLA, CA, Oct. 19, 2023 (GLOBE ...
AlloCAR70-NKT is an off-the-shelf immunotherapy using engineered immune cells to target kidney cancer without patient-specific customization. The therapy addresses challenges of traditional CAR-T ...
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell BrightPath Bio (Tokyo Stock Exchange Growth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results